Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCM Adjuvant Therapy in TNBC
NCT04403529Phase 3Unknown
- Sponsor
- Fudan University
- Start
- May 2020
- Primary completion
- May 2024
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in triple-negative breast cancer (TNBC) (2 arms), sponsored by Fudan University. Primary endpoints: Disease Free Survival at 3 years, Quality of Life (EORTC QLQ-C30) at 3 years and 1 more. Status: unknown.
02
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04403529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04403529.